Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors
J Natl Compr Canc Netw. 2024 Feb;22(1):e237116. doi: 10.6004/jnccn.2023.7116.ABSTRACTOver the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They include the broader availability of cost-effective generic imatinib, and soon other generic second-generation tyrosine kinase inhibitors (TKIs). Access to affordable generics means that all patients with CML-CP should have access to safe and highly effective lifelong therapies. When overall survival is the treatment endpoint, imatinib provides a good treatment value...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Fadi G Haddad Hagop Kantarjian Source Type: research
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2024 Feb;22(1):43-69. doi: 10.6004/jnccn.2024.0007.ABSTRACTChronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Neil P Shah Ravi Bhatia Jessica K Altman Maria Amaya Kebede H Begna Ellin Berman Onyee Chan Joan Clements Robert H Collins Peter T Curtin Daniel J DeAngelo Michael Drazer Lori Maness Leland Metheny Sanjay Mohan Joseph O Moore Vivian Oehler Keith Pratz Isk Source Type: research
Identification and clinical implications of recurrent PAX5::MLLT3 fusion in lymphoid blastic phase chronic myeloid leukemia
Int J Lab Hematol. 2024 Feb 23. doi: 10.1111/ijlh.14245. Online ahead of print.NO ABSTRACTPMID:38389449 | DOI:10.1111/ijlh.14245 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - February 23, 2024 Category: Hematology Authors: Lijun Wang Yu Chen Qingyuan Wang Meng Xiang Zhao Zeng Zhibo Zhang Fenghong Zhang Suning Chen Mengxing Xue Source Type: research
Genetically predicted telomere length and the risk of 11 hematological diseases: a Mendelian randomization study
CONCLUSIONS: The MR analysis revealed a positive association between genetically predicted longer TL and an increased risk of developing ALL, AML, CLL, MANTLE, and HODGKIN. This study further supports the notion that cells with longer TL have greater proliferative and mutational potential, leading to an increased risk of certain HDs.PMID:38393686 | DOI:10.18632/aging.205583 (Source: Aging)
Source: Aging - February 23, 2024 Category: Biomedical Science Authors: Yimin Wang Qi Liu Shibing Liang Minghao Yao Huimin Zheng Dongqing Hu Yifei Wang Source Type: research
Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors
J Natl Compr Canc Netw. 2024 Feb;22(1):e237116. doi: 10.6004/jnccn.2023.7116.ABSTRACTOver the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They include the broader availability of cost-effective generic imatinib, and soon other generic second-generation tyrosine kinase inhibitors (TKIs). Access to affordable generics means that all patients with CML-CP should have access to safe and highly effective lifelong therapies. When overall survival is the treatment endpoint, imatinib provides a good treatment value...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Fadi G Haddad Hagop Kantarjian Source Type: research
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2024 Feb;22(1):43-69. doi: 10.6004/jnccn.2024.0007.ABSTRACTChronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Neil P Shah Ravi Bhatia Jessica K Altman Maria Amaya Kebede H Begna Ellin Berman Onyee Chan Joan Clements Robert H Collins Peter T Curtin Daniel J DeAngelo Michael Drazer Lori Maness Leland Metheny Sanjay Mohan Joseph O Moore Vivian Oehler Keith Pratz Isk Source Type: research
Identification and clinical implications of recurrent PAX5::MLLT3 fusion in lymphoid blastic phase chronic myeloid leukemia
Int J Lab Hematol. 2024 Feb 23. doi: 10.1111/ijlh.14245. Online ahead of print.NO ABSTRACTPMID:38389449 | DOI:10.1111/ijlh.14245 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - February 23, 2024 Category: Hematology Authors: Lijun Wang Yu Chen Qingyuan Wang Meng Xiang Zhao Zeng Zhibo Zhang Fenghong Zhang Suning Chen Mengxing Xue Source Type: research
Genetically predicted telomere length and the risk of 11 hematological diseases: a Mendelian randomization study
CONCLUSIONS: The MR analysis revealed a positive association between genetically predicted longer TL and an increased risk of developing ALL, AML, CLL, MANTLE, and HODGKIN. This study further supports the notion that cells with longer TL have greater proliferative and mutational potential, leading to an increased risk of certain HDs.PMID:38393686 | DOI:10.18632/aging.205583 (Source: Aging)
Source: Aging - February 23, 2024 Category: Biomedical Science Authors: Yimin Wang Qi Liu Shibing Liang Minghao Yao Huimin Zheng Dongqing Hu Yifei Wang Source Type: research
Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors
J Natl Compr Canc Netw. 2024 Feb;22(1):e237116. doi: 10.6004/jnccn.2023.7116.ABSTRACTOver the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They include the broader availability of cost-effective generic imatinib, and soon other generic second-generation tyrosine kinase inhibitors (TKIs). Access to affordable generics means that all patients with CML-CP should have access to safe and highly effective lifelong therapies. When overall survival is the treatment endpoint, imatinib provides a good treatment value...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Fadi G Haddad Hagop Kantarjian Source Type: research
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2024 Feb;22(1):43-69. doi: 10.6004/jnccn.2024.0007.ABSTRACTChronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Neil P Shah Ravi Bhatia Jessica K Altman Maria Amaya Kebede H Begna Ellin Berman Onyee Chan Joan Clements Robert H Collins Peter T Curtin Daniel J DeAngelo Michael Drazer Lori Maness Leland Metheny Sanjay Mohan Joseph O Moore Vivian Oehler Keith Pratz Isk Source Type: research
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
Leukemia, Published online: 23 February 2024; doi:10.1038/s41375-024-02183-0Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry (Source: Leukemia)
Source: Leukemia - February 23, 2024 Category: Hematology Authors: Ekaterina Chelysheva Jane Apperley Anna Turkina Mohamed A. Yassin Delphine Rea Franck E. Nicolini Daniela Barraco Khamida Kazakbaeva Sukhrob Saliev Adi Shacham Abulafia Salam Al-Kindi Jennifer Byrne Harry F. Robertson Marco Cerrano Roman Shmakov Evgenia P Source Type: research
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions
AbstractPurpose of ReviewThe discovery that patients suffering from chronic myeloid leukemia who obtain deep and long-lasting molecular responses upon treatment with tyrosine kinase inhibitors may maintain their disease silent for many years after therapy discontinuation launched the era of treatment-free remission as a key management goal in clinical practice. The purpose of this review on treatment-free remission is to discuss clinical advances, highlight knowledge gaps, and describe areas of research.Recent FindingsPatients in treatment-free remission are a minority, and it is believed that some may still retain a reser...
Source: Current Hematologic Malignancy Reports - February 23, 2024 Category: Hematology Source Type: research
Physical exercise recommendations for patients with chronic myeloid leukemia based on individual preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)
ConclusionCounseling and motivation of CML patients to be physically active should be part of the standard of care as well as support for implementation. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - February 21, 2024 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 16, Pages 848: Artificial Intelligence-Based Management of Adult Chronic Myeloid Leukemia: Where Are We and Where Are We Going?
Gatta
Artificial intelligence (AI) is emerging as a discipline capable of providing significant added value in Medicine, in particular in radiomic, imaging analysis, big dataset analysis, and also for generating virtual cohort of patients. However, in coping with chronic myeloid leukemia (CML), considered an easily managed malignancy after the introduction of TKIs which strongly improved the life expectancy of patients, AI is still in its infancy. Noteworthy, the findings of initial trials are intriguing and encouraging, both in terms of performance and adaptability to different contexts in which AI can be applied. Ind...
Source: Cancers - February 20, 2024 Category: Cancer & Oncology Authors: Simona Bernardi Mauro Vallati Roberto Gatta Tags: Review Source Type: research
